Gensaic
Developer of tissue-selective in vivo delivery systems and multifunctional siRNA therapeutics for cardiometabolic and age-related diseases. Combines high-diversity in vivo ligand screens, protein-language-model driven sequence-to-function discovery, siRNA payload conjugation, and in vivo dual-gene validation to enable tissue-targeted RNA interference.
Industries
Nr. of Employees
small (1-50)
Products
Obesity + Lean Mass program
Preclinical program targeting adipose and skeletal muscle using tissue-selective delivery and multifunctional siRNA constructs; listed at lead optimization stage on the public pipeline.
Obesity + MASH (MAFLD) program
Preclinical program targeting adipose and liver using tissue-selective delivery and multifunctional siRNA constructs; listed at lead optimization stage on the public pipeline.
Cardiometabolic disease discovery program
Discovery-stage programs applying the tissue-targeting platform and multifunctional siRNA constructs to identify interventions for cardiometabolic disease.
The GensaicFORGE Engine
An AI-guided discovery and delivery platform utilizing unbiased tissue-targeting screening and protein language models to engineer tissue-specific in vivo delivery systems and multifunctional siRNA constructs.
Obesity + MASH
Therapeutic program targeting adipose tissue and the liver for obesity and metabolic dysfunction-associated steatohepatitis.
Cardiometabolic Disease
Therapeutic program targeting adipose tissue for cardiometabolic indications.
Obesity + Lean Mass program
Preclinical program targeting adipose and skeletal muscle using tissue-selective delivery and multifunctional siRNA constructs; listed at lead optimization stage on the public pipeline.
Obesity + MASH (MAFLD) program
Preclinical program targeting adipose and liver using tissue-selective delivery and multifunctional siRNA constructs; listed at lead optimization stage on the public pipeline.
Cardiometabolic disease discovery program
Discovery-stage programs applying the tissue-targeting platform and multifunctional siRNA constructs to identify interventions for cardiometabolic disease.
The GensaicFORGE Engine
An AI-guided discovery and delivery platform utilizing unbiased tissue-targeting screening and protein language models to engineer tissue-specific in vivo delivery systems and multifunctional siRNA constructs.
Obesity + MASH
Therapeutic program targeting adipose tissue and the liver for obesity and metabolic dysfunction-associated steatohepatitis.
Cardiometabolic Disease
Therapeutic program targeting adipose tissue for cardiometabolic indications.
Expertise Areas
- Tissue-targeted in vivo delivery
- siRNA/RNAi therapeutics
- AI-driven protein/ligand design
- Preclinical in vivo screening and validation
Key Technologies
- Protein language models (sequence-to-function)
- High-diversity in vivo ligand library screening
- siRNA payload conjugation
- Ionizable lipid nanoparticle formulations
News & Updates
Board appointment of Jill Milne, former CEO of related biotech companies, as the company advances its cardiometabolic programs and RNAi platform.
Board appointment of Neil Exter, retired partner at Third Rock Ventures, as the company advances its cardiometabolic programs and RNAi platform.
Appointment of Liang Schweizer to the Board of Directors.
Collaboration to develop tissue-targeted therapies for cardiometabolic diseases, combining the company's tissue-selective delivery platform with external therapeutic expertise.
News articles covering a deal to leverage the tissue-selective delivery technology for therapeutics beyond the liver.
Coverage describing the collaboration as combining AI-powered protein design with efforts to enable selective transport of therapeutics to specific tissues.
Board appointment of Jill Milne, former CEO of related biotech companies, as the company advances its cardiometabolic programs and RNAi platform.
Board appointment of Neil Exter, retired partner at Third Rock Ventures, as the company advances its cardiometabolic programs and RNAi platform.
Appointment of Liang Schweizer to the Board of Directors.
Collaboration to develop tissue-targeted therapies for cardiometabolic diseases, combining the company's tissue-selective delivery platform with external therapeutic expertise.
News articles covering a deal to leverage the tissue-selective delivery technology for therapeutics beyond the liver.
Coverage describing the collaboration as combining AI-powered protein design with efforts to enable selective transport of therapeutics to specific tissues.